Posted on 354
PerkinElmer, Inc., (NYSE: PKI) a global leader committed to innovating for a healthier world, today provided an update on the COVID-19 Valencia Branch Laboratory’s (VBL) accreditation process. The VBL is operated by PerkinElmer in partnership with the California Department of Public Health (CDPH). The VBL started operations on November 1, 2020, and Laboratory Field Services (LFS) performed its routine inspection on December 8, 2020.
The VBL received LFS’s routine inspection report on February 19, 2021, and PerkinElmer’s response is due by March 1, 2021. During the months of December and January, the VBL supplied additional information at LFS’s request. Upon review, it appears that LFS had not yet incorporated this extensive information into its routine inspection report. PerkinElmer believes that the deficiencies identified by LFS have long since been resolved.
PerkinElmer, Inc.: PerkinElmer to Acquire Oxford Immunotec Global PLC
Transaction expected to be completed in the first half of 2021
PerkinElmer, Inc. (NYSE: PKI) (
Oxford Immunotec or the
Company ) are pleased to announce they have reached an agreement on terms under which PerkinElmer will acquire Oxford Immunotec (the
Acquisition ). It is intended that the Acquisition will be implemented by means of a U.K. High Court of Justice-sanctioned scheme of arrangement under Part 26 of the U.K. Companies Act 2006 between Oxford Immunotec and its shareholders (the
Scheme
Under the terms of the Acquisition, Oxford Immunotec shareholders will be entitled to receive USD 22.00 in cash for each outstanding ordinary share (